Cantor Fitzgerald Issues Positive Outlook for PRE Earnings

Prenetics Global Limited (NASDAQ:PRE) – Equities researchers at Cantor Fitzgerald lifted their FY2024 EPS estimates for Prenetics Global in a research report issued on Wednesday, December 4th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($3.30) per share for the year, up from their prior forecast of ($3.32). Cantor Fitzgerald has a “Overweight” rating and a $9.00 price target on the stock. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.32) per share.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Monday, October 7th. The company reported ($0.88) earnings per share for the quarter. The firm had revenue of $5.94 million during the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%.

Prenetics Global Trading Up 3.1 %

Shares of NASDAQ PRE opened at $5.16 on Friday. The stock has a market cap of $47.10 million, a P/E ratio of -1.29 and a beta of -0.18. Prenetics Global has a twelve month low of $2.85 and a twelve month high of $7.84. The stock has a 50 day moving average of $4.57 and a two-hundred day moving average of $5.16.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.